News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Basler AG confirms business figures for 2023: Annual result confirmed, supervisory board supports proposal for appropriation of profits, outlook for 2024
Basler AG confirms 2023 business figures, supervisory board supports profit appropriation proposal, and provides outlook for 2024. Sales and profit declined with strategic restructuring implemented -
COMMUNIQUÉ RÉGLEMENTÉ
bioMérieux receives Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux receives 510(k) clearance and CLIA-waiver for BIOFIRE SPOTFIRE R/ST Panel, enhancing diagnostic capabilities for respiratory and sore throat infections globally -
COMMUNIQUÉ RÉGLEMENTÉ
bioMérieux obtient l'agrément 510(k) et la dérogation CLIA pour le panel BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST)
bioMérieux obtient l'agrément 510(k) et la dérogation CLIA pour le panel BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST). Cette avancée renforce l'offre de tests rapides et innovants pour le diagnostic des infections respiratoires et pharyngées -
COMMUNIQUÉ DE PRESSE
lePERMISLIBRE announces its 2023 annual results
lePERMISLIBRE announces its 2023 annual results with +13% revenue growth, reduced operating loss, and new innovations. Lyon, March 27, 2024 - lePERMISLIBRE, a pioneer in online driving school in France, published its audited 2023 results -
-
COMMUNIQUÉ DE PRESSE
Avolta embarks on 10-year journey with 8 new F&B stores at India’s new Noida International Airport, grows India footprint to more than 100 stores
Avolta AG secures 10-year F&B concessions at Noida International Airport, expanding India presence to 100+ stores. Partnership aims to enhance traveler experience with global and local F&B brands -
COMMUNIQUÉ DE PRESSE
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 29.02.24.
ABIVAX communique le nombre d'actions et de droits de vote au 29/02/2024, conformément aux règlements financiers. Abivax est une société de biotechnologie en phase clinique axée sur le développement de traitements thérapeutiques
